Jan 05, 2017 13:45 pm UTC| Business
BURLINGTON, Mass., Jan. 05, 2017 -- Avid® (Nasdaq:AVID) today announced that Fenerbahçe Sports Club, the Turkish multi-sports organisation, has made the transition from SD to HD production with an end-to-end sports...
Gemphire Therapeutics Provides Clinical Update
Jan 05, 2017 13:40 pm UTC| Business
Enrollment in the ROYAL-1 Clinical Trial Investigating Gemcabene in Hypercholesterolemia Is Ahead of Plan and Expected to be Completed This Month – Data Expected in the Third Quarter of 2017 Interim Data from the...
Canada Surge Arresters Market expected to Reach USD 105.84 Million by 2022: Zion Market Research
Jan 05, 2017 13:32 pm UTC| Business
Sarasota, FL, Jan. 05, 2017 -- Zion Market Research has published a new report titled “Surge Arresters Market (Low Voltage Surge Arresters, Medium Voltage Surge Arresters and High Voltage Surge Arresters) for...
NETGEAR Demonstrates the Best of the Connected World for CES 2017
Jan 05, 2017 13:31 pm UTC| Business
LAS VEGAS, Nev., Jan. 05, 2017 -- NETGEAR®, Inc. (NASDAQ:NTGR), the leading provider of networking devices that power today’s smart home and small and medium-sized businesses (SMBs), is introducing a range of new...
NETGEAR Demonstrates the Best of the Connected World for CES 2017
Jan 05, 2017 13:31 pm UTC| Business
LAS VEGAS, Nev., Jan. 05, 2017 -- NETGEAR®, Inc. (NASDAQ:NTGR), the leading provider of networking devices that power today’s smart home and small and medium-sized businesses (SMBs), is introducing a range of new...
Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017
Jan 05, 2017 13:31 pm UTC| Business
NEWTOWN, Pa., Jan. 05, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that...
Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017
Jan 05, 2017 13:31 pm UTC| Business
NEWTOWN, Pa., Jan. 05, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that...